What the April 2026 FDA peptide reclassification path actually means
A formal process is underway. It is not the same as a final decision.
TL;DR
- A February 2026 HHS announcement proposed returning several Category 2 peptides — including BPC-157, TB-500, and others — to Category 1 status for 503A compounding.
- As of April 2026, the formal Federal Register notice required to change the framework has not been issued.
- The Pharmacy Compounding Advisory Committee meeting in July 2026 is the next visible milestone in the process.
What it is
“FDA peptide reclassification” is shorthand for moving a peptide between Category 1 (allowed for 503A compounding) and Category 2 (not currently allowed). The framework comes from the FDA’s bulks list rulemaking under the Drug Quality and Security Act (DQSA), which governs what compounding pharmacies are permitted to mix.
In February 2026, HHS announced that several peptides previously moved to Category 2 should be returned to Category 1. That announcement was a policy direction — not the legal change itself.
How it works
Picture the procedure as a multi-stop train, not a single stop. The train looks like this:
- HHS or FDA policy announcement. Signals direction. Not legally binding.
- Pharmacy Compounding Advisory Committee (PCAC) review. A federal advisory committee evaluates the science and the compounding context.
- Federal Register proposed rule. The legal proposal goes public for comment.
- Public comment period. Stakeholders submit comments — patients, pharmacists, clinicians, manufacturers.
- Final rule in the Federal Register. The legal change takes effect on the date the final rule specifies.
The April 2026 status is between stops 1 and 2. The signal has been given. The legal mechanism has not yet moved.
Who asks about it
People come to this question through three doors: news coverage of the February 2026 HHS announcement, frustration with current Category 2 access limits, and clinician communication about what may change later in the year.
What the research says
The procedural framework is described in the FDA’s compounding Q&A and in the Federal Register process for rulemaking (FDA — Compounding Q&A; Federal Register). The clinical evidence base for the affected peptides is largely preclinical, which is part of what PCAC will evaluate.
What to know before considering it
Until a final rule publishes, the law has not changed. Avoid sources that describe Category 2 peptides as “legal again” before the Federal Register confirms it. Any clinical use of the affected peptides requires a licensed clinician evaluation under the current framework.
The Halftime POV
A policy announcement is a starting gun, not a finish line. We want patients to know what is happening, what is not yet happening, and what to watch for. The honest answer in April 2026 is “in motion, not finished.”
Related reading:
- The February 2026 HHS announcement on peptide reclassification
- Category 1 vs Category 2 peptides: the access framework
- What the July 2026 PCAC meeting could change
FAQ
Q: What is the April 2026 FDA peptide reclassification? A: It refers to the procedural path the FDA is following after the February 2026 HHS announcement that proposed returning several Category 2 peptides to Category 1 status for 503A compounding. The path requires a formal Federal Register notice and a Pharmacy Compounding Advisory Committee review.
Q: Did the FDA already approve compounding for BPC-157 and TB-500? A: Not yet. As of April 2026, the procedural path is in motion but the formal Federal Register notice has not been issued. Until that notice publishes and is finalized, BPC-157, TB-500, and other Category 2 peptides remain unavailable from 503A compounding pharmacies.
Q: What is the next milestone to watch? A: The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet in July 2026. The agenda includes peptide compounding eligibility. PCAC’s recommendation feeds into the FDA’s decision-making, but PCAC does not itself change the law.
Disclaimer
As of April 2026, several peptides discussed in this article — including BPC-157 and TB-500 — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- FDA. Compounding and the FDA: Questions and Answers.
- Federal Register — Daily journal of the United States Government.
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Sources & references
- federalregister.gov — https://www.federalregister.gov/
- fda.gov — https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
